DocWire News Editors

DocwireNews

Independent predictors of early relapse multiple myeloma (MM) include TP53 mutation, high LDH levels, amp1q and IGLL5 mutation, according to the findings of a study presented at the 17th International Myeloma Workshop.To conduct this study, the researchers analyzed data on 1,151 patients enrolled in the Multiple Myeloma Research Foundation (MMRF) CoMMpass trial. The cohort was comprised of 760 real-world patients and 166 patients enrolled in clinical trials. &nbsp;The data cut-off for patients co-enrolled in the NCT02203643 study was May 30, 2018. Patients with a time-to-progression (TTP) of 18 months or less were defined as early progressors, and all cytogenetic data were defined using SeqFISH. Each patient&rsquo;s therapy was categorized according to their initial induction therapy, autologous stem-cell transplantation (ASCT) and maintenance therapy. Subsequently, the researchers performed a univariate analysis of clinical and biological factors.The most frequent induction therapy was VRd followed by bortezomib + chemotherapy triplet, and maintenance was achieved by 74% of evaluable patients with early progression occurring in 21% of patients. Among patients defined as early progressors, 16.2% were primary refractory, 46.6% relapsed while receiving active treatment during the first year. The researchers adjusted the multivariate logistic regression model to avoid any bias. They observed that independent factors increasing the risk of early progression were TP53 mutation (OR=3.63, P&lt;0.001), high LDH levels (OR=2.23, P=0.026), amp1q positivity (OR=1.56, P=0.027) and IGLL5 mutation (OR=1.73, P=0.025).&ldquo;With the limitations of a mixed real-world + clinical-trial population and a nonrandomized evaluation, treatment intensification with ASCT and maintenance lowered the risk of early progression,&rdquo; the researchers wrote in their conclusion.D&rsquo;Agostino, M, et al. Clinical and Biological Early Relapse Predictors in Multiple Myeloma: An Analysis from the MMRF CoMMpass Study. Presented at the 17th International Myeloma Workshop; September 12-15, 2019; Boston, MA.

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Clinical and Biological Early Relapse Predictors in Multiple Myeloma: An Analysis from the MMRF CoMMpass Study

International Myeloma Workshop 2019

Independent predictors of early relapse multiple myeloma (MM) include TP53 mutation, high LDH levels, amp1q and IGLL5 mutation

Clinical and Biological Early Relapse Predictors in Multiple Myeloma: An Analysis from the MMRF

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe